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Abstract
Background: The number of stunted children has fallen globally but continues to increase in Africa. Stunting is
estimated to contribute to 14–17% of child deaths under 5 years of age and is a risk factor for poor cognitive and
motor development and educational outcomes. Inadequate dietary intake and disease are thought to be the
immediate causes of undernutrition and stunting. However, improving infant diets through complementary feeding
interventions has been shown to only modestly reduce stunting. Multiple observational studies demonstrate a dose
response relationship between fetal and post-natal aflatoxin exposure and reduced linear growth.
Methods: This community-based cluster randomized trial will measure the effect of a reduced aflatoxin diet on
length-for-age Z scores at 18 months in central Tanzania. All 52 health facilities in the Kongwa District of Dodoma
Region were randomized into two groups. Starting at 6 months of age, participants in the intervention group
receive a low-aflatoxin pre-blended porridge flour containing maize and groundnut (ratio 4:1 respectively) and low-
aflatoxin groundnut flour, whereas in the control group the same porridge mix and groundnut flour are promoted
through education but acquired by the household. Both groups will receive the same infant and young child
feeding education and a thermos flask. A total of 3120 infants between 6 weeks and 3months of age will be
recruited into the study over 1 year. Data will be collected four times – at recruitment and when the infants are 6,
12 and 18 months of age. In a cohort of 600 infants, additional data will be collected at 9 and 15 months of age.
The primary outcome is length-for-age at 18 months. Secondary outcomes include the Z scores for weight-for-age,
middle upper arm circumference and head circumference, and the blood biomarker aflatoxin-albumin in the full
sample, with the urine biomarker aflatoxin M1 analyzed in the cohort only.
Discussion: Better understanding the etiology of childhood stunting can lead to more appropriate interventions
and policies to further reduce linear growth faltering and meet the Sustainable Development Goals.
Trial registration: NCT03940547, (April 24, 2019).
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In 2018, 21.9% of children under 5 were stunted globally,
the heaviest burden in South Asia and Eastern Africa
[1]. Stunting is estimated to contribute to 14–17% of
child deaths under 5 years of age and is associated with
poor cognitive and motor development and educational
outcomes [2–6]. The etiology of stunting has long been
attributed to inadequate dietary intake and gastrointes-
tinal illness, including diarrhea [7]. However, multiple
reviews and recent large trials of nutrition education,
complementary feeding programs and water, sanitation
and hygiene (WASH) interventions to reduce stunting
have shown modest or no effects on linear growth in
food insecure populations, those who would theoretically
benefit the most from such intervention [8–13]. In three
systematic reviews, the effect of provision of comple-
mentary foods with or without education on LAZ was
small to moderate, with effect sizes ranging from 0.10–
0.39 [9, 10, 14]. It is therefore plausible that other factors
contribute to stunting, including mycotoxin exposure
[15–17].
Mycotoxins, including aflatoxin (AF) and fumonisin
(FUM) are naturally occurring secondary metabolites
produced by fungi that colonize foodstuffs. Approxi-
mately 0.5 billion people, mainly living in developing
countries, are at risk of being chronically exposed to
dietary AF at high levels [18]. Maize and groundnut, two
key staples in eastern and southern Africa, are particu-
larly vulnerable to contamination by AF; maize is vulner-
able to contamination by FUM as well. Exposure to AF
in low-income populations, especially those in rural sub-
Saharan Africa, is particularly problematic because the
diet is monotonous, largely based on AF-prone crops,
and grown and stored under conditions that predispose
them to contamination.
AF are proven human liver carcinogens and intermittent
outbreaks of extremely high levels of AF consumption
cause acute and often fatal liver toxicosis [19, 20]. The ef-
fects of less extreme AF exposure during critical periods
of early-life development are not understood, although AF
and FUM are suspected of contributing to stunting. The
pathways between AF consumption and growth impair-
ment are not known, however one plausible mechanism is
propagation of environmental enteric dysfunction (EED),
a sub-clinical disorder that damages the lining of the small
intestine, causing mucosal damage and impairing its func-
tion [15, 17, 21]. EED can lead to stunting by causing nu-
trient malabsorption, growth hormone resistance, and
impaired bone growth and remodeling [22]. It is hypothe-
sized that AF and FUM share a pathway that overlaps with
EED, which may include interactions with both gastro-
intestinal infection and liver toxicity leading to impaired
protein synthesis or homeostatic function [16]. Additional
mechanisms for AF driven growth faltering have been
suggested but remain unproven [23, 24].
Multiple observational studies have shown an associ-
ation between fetal and post-natal aflatoxin exposure
and linear growth [25–27]. In rural Benin and Togo, the
concentration of the blood biomarker, serum aflatoxin
albumin (AF-alb), was associated with growth deficien-
cies among young children from 9months to 5 years, as
demonstrated by significant dose-response relationship
with both length-for-age (LAZ) and weight-for-age Z
scores (WAZ) [25]. In a subsequent longitudinal study
in rural Benin, infants in the highest quartile of AF- alb,
compared to the lowest quartile were 1.7 cm shorter
after 8 months [26]. A longitudinal survey of AF expos-
ure during pregnancy and via early introduction of com-
plementary foods examined the relationship between
exposure and infant growth from birth to 52 weeks. A
significant inverse relationship between maternal AF ex-
posure and infant growth velocity was observed [27]. A
more statistically significant effect on growth was seen
when models included early infant exposure (measures
at week 16 years of age) in addition to maternal AF, sug-
gesting multiple exposure windows may be possible to
affect and or mitigate AF induced growth effects.
An observational study in Tanzania assessed the ef-
fects of AF and FUM exposure on attained LAZ at 12
months [28]. Urinary FUM was negatively associated
with LAZ (p = 0.01), with children in the highest quartile
of exposure 1.8 cm shorter than children in the lowest
quartile of exposure; the negative association between
AF-alb and LAZ did not reach statistical significance,
however AF-alb levels were lower compared to studies
in West Africa described above. The MAL-ED study in
Nepal also did not find an association between AF con-
sumption and stunting, but it too was conducted in an
area of lower AF exposure and lower prevalence of
stunting compared to West Africa [29].
Most of these observational studies have been small
with varying assessment and analytic methods used be-
tween them, making statistical comparisons between
them difficult. Yet taken together, these results suggest a
potential threshold of exposure above which AF driven
growth faulting occurs.
One randomized trial has assessed the effect of re-
duced AF consumption on linear growth [30]. The study
did not find an improvement on LAZ at 18 months in
the intervention group, despite a 27% decrease in the
blood biomarker, AF-alb [31]. However, there was a sig-
nificant difference in LAZ at midpoint, even though AF-
alb did not differ between groups at midpoint. Overall
AF-alb was modest in this study when compared to data
from West Africa [20–22]. Confounding interpretation
of these results, 27 % of recruited infants were not in-
cluded in the analysis of the primary outcome and 65%
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of AF-alb samples were analyzed due to loss of follow-
up.
To fill current gaps in knowledge about the effect of
AF exposure on child growth we designed a community-
based cluster randomized trial to assess the effect of a
low AF diet on linear growth. Our intervention was de-
signed to target feeding behaviors for the index child
and to specifically isolate the effect of AF consumption
between the intervention and control groups. We will
collect contextual data about levels of AF contamination
in infant foods and multiple human biomarkers and as-
sess feeding practices and adherence to our intervention
at multiple time points to better understand the path-
ways between AF ingestion and growth retardation.
Methods
Aims
This two-group cluster randomized trial (CRT) is de-
signed to test the hypothesis that provision of a comple-
mentary food porridge flour and separate groundnut
flour, both with very low levels of AF (AFB1 < 5 ppb) will
be associated with better linear growth in infants be-
tween 6 and 18months of age compared to infants who
consume complementary porridge and foods made with
similar ingredients and groundnut flour, but acquired by
the household.
The primary objective of the trial is to measure the ef-
fect of a low-AF diet on length-for-age Z scores at 18
months. Select secondary outcomes are to:
1. Determine the effect of an intervention to reduce
AF exposure on LAZ scores at 12 months and
stunting at 12 and 18 months
2. Determine the effect of an intervention to reduce
AF exposure on WAZ and underweight at 12 and
18months
3. Examine the effect of an intervention to reduce AF
exposure on mid-upper arm circumference
(MUAC) and head circumference at 12 and 18
months
4. Assess the effect of an intervention to reduce AF
exposure on the blood biomarker AF-alb at 12 and
18months
5. Assess the effect of an intervention to reduce AF
exposure on the urinary biomarker AFM1 in a
cohort of 600 infants at 9, 12, 15 and 18 months
A full list of all 14 secondary outcomes is included in
Appendix 1.
Study setting
The trial is being conducted in Kongwa District,
Dodoma Region of Tanzania. This district was selected
because stunting in the region is 37%, slightly above the
national average, and there were 8000 live births in
2017, enough to support the trial’s sample size [32]. The
unit of randomization is a health facility. All 52 health
facilities in the district (1 district hospital, 4 health cen-
ters and 46 dispensaries) were randomized into the con-
trol or intervention group. Two community health
workers (CHWs) per health facility were selected by the
management of the facility to be employed part-time by
the research project. These CHWs were trained by Tan-
zanian Food and Nutrition Center trainers in March of
2019 in infant and young child feeding (IYCF) and lead
IYCF education sessions for trial mothers in their com-
munities. The majority of data collection, including col-
lection of all biological samples, is performed at the
health centers.
Recruitment
Recruitment into the trial is conducted through each
health facility using Expanded Program on Immunization
(EPI) attendance records. EPI coverage is > 95% in
Kongwa District [33]. All 52 facilities are visited in a
“round” of recruitment over 5–6 weeks, with recruitment
ongoing for one calendar year. The names of the infants
who attended the 42 day EPI visit since the previous
round’s visit are recorded from the facility’s register. In se-
quential order by visit date, mothers of these infants are
visited in their homes, screened for eligibility and invited
into the study, until the target number of women agree to
participate. The informed consent procedure is performed
by a trained data collector at the time of recruitment.
Inclusion and exclusion criteria
Inclusion criteria:
1. Babies > 6 weeks old and < 4 months old, who seek
EPI from a randomized health facility and reside in
Kongwa District
Exclusion criteria, assessed at recruitment and again at
the 6-month visit:
1. A baby with a disability that preclude normal
feeding and swallowing
2. A parent who refuses to consent to assigned
intervention
3. An infant who has shown signs of a potential
groundnut allergy (assessed the first time mother
reports groundnut consumption)
4. An infant who is a twin
5. The mother plans to travel for more than two
months at or after the randomized intervention
begins
6. A mother below 16 years of age
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Formative research
The trial intervention was designed following multiple
years of formative research in Kongwa District. We col-
lected food samples across the district to overlay AF
contamination of foods with stunting and birthrates
using GIS. In the year prior to the trial launch, we col-
lected 387 food samples at two time points from 115
households in 24 villages across Kongwa, which revealed
frequent AF contamination of both maize and ground-
nuts (Ngure et al., manuscript in prep). The levels of AF
contamination for groundnut ranged between 0.6–3600
ppb, with 56% of samples > 20 ppb. For maize, 6% of
samples were > 20 ppb with a range between 0.4–55.5
ppb. Other foods reported consumed by infants, in-
cluded millet, finger millet, rice, sorghum and sunflower
seeds, of which 5% had AF > 20 ppb. The AF contamin-
ation in these foods was similar in frequency and levels
to previous studies linking AF to growth faltering in
West Africa and Zimbabwe [27, 34, 35].
Five focus groups and recipe trials were conducted to
test the acceptability of the proposed pre-blended por-
ridge flour of 3 or 4 parts maize to 1 part groundnut,
the advice of the District Nutrition Officer, and to in-
form IYCF educational messages. From these discus-
sions, two short-term trials of improved practices (TIPS)
were conducted as proof of concept of the main trial
intervention [36]. The first TIPS tested mothers’ accept-
ability and responsiveness to the control condition, pro-
motion of a pre-blended porridge flour made of maize
and groundnut and the addition of groundnut to relishes
or sauces consumed by the infant (manuscript in prep).
Briefly, in this first trial of 17 days, 66% of infants at
baseline and 71% of infants at follow-up (n = 35) con-
sumed groundnut on the previous day. Slightly more
mothers reported adding groundnut in porridges and
vegetable relish at follow-up than baseline, indicating a
willingness to incorporate educational messages into in-
fant feeding practices. The second trial tested mothers’
acceptability of the intervention condition (provision of
a pre-blended porridge flour). Three day consecutive
urine samples were collected both at baseline and
follow-up in all infants (n = 37). Provision of low-AF
pre-blended porridge flours reduced the prevalence of
detectable urinary AFM1 by 81% in following
provision of AF-free lishe for 7–10 days, indicating
high acceptability.
Based on these findings, we refined our trial interven-
tion to promote and provide pre-blended flours at a ra-
tio of 4 parts maize to 1 part groundnut, the median
ratio of practices found by mothers in the 24 h recalls
collected in the mini-trials. This decision will reduce the
potential for a difference in dietary intake between
groups and reduce ethical concerns of increasing
groundnut consumption in the control group. Secondly,
the trial will use a separate low AF groundnut flour
in the intervention group, in addition to pre-blended
maize and groundnut flour, as groundnut was com-
monly used to flavor foods consumed by the infant
and the household and is a potential source of AF ex-
posure. Finally, a thermos flask will be provided to all
trial mothers to hygienically store cooked porridge
throughout the day.
Trial intervention
Beginning when the index infant is 6 months of age, data
collectors and research staff meet with mothers at each
health facility one time per month to collect data and
deliver the research supplies to participants. Following
data collection, mothers in the intervention group re-
ceive pre-blended porridge flour in sealed plastic con-
tainers. Fifty grams/day is provided for 6–8 month olds,
60/day grams for 9–11months and 75 g/day for 12–18
month olds, and containers contain an additional buffer
of 10–15 g per day to account for any loss or sharing in
the household. These amounts were calculated to pro-
vide all of the caloric needs for 6–8month olds and pro-
gressively less calories and macronutrients for older
infants as their diets are more diverse, while taking into
account local feeding practices. The intervention group
will also receive 1 kg of low-AF groundnut flour each
month for between 6 and 18 months. Mothers in the
control group receive skin lotion every month. At the 6
month visit all mothers are given a thermos flask and a
plastic scoop to measure the appropriate amount of por-
ridge flour (Table 1).
Between the time of recruitment (between 6 weeks and
3months of age) and the start of the randomized inter-
vention at 6 months of age, all trial mothers are invited
to a 4 and 5month IYCF education session led by local
CHWs, with a focus on promotion of exclusive breast-
feeding, hand washing, and preparing to feed at 6
months, based on Government of Tanzania education
materials [37]. Between 8 and 11months of age, all
mothers are invited to two additional infant and young
child feeding education sessions that focus on age-
appropriate feeding frequency, diet quality and diversity,
and the importance of continued breastfeeding. At the
monthly pick-up of the flours or skin lotion, the CHWs
lead a short education session to reinforce the main
IYCF messages taught at the longer sessions with add-
itional messages about hygienic storage of all infant food
flours. The only difference in messages between groups
is that intervention group mothers are advised that the
provided porridge flour is for the index child only.
There is no blinding in this study, as all parties will be
able to see what is received by the mother – pre-blended
flour and groundnut flour or lotion.
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Complementary Food production
Critical to the trial’s success is the production of low-AF
porridge and groundnut flours. We have partnered with
a Tanzanian flour miller to produce the research foods.
Procurement of maize and groundnut will be performed
collaboratively between the researchers and the miller.
Pendo groundnut variety, the type commonly consumed
in Kongwa, will be sourced mainly from Dodoma region
to mimic local consumption and quality. A multiple
stage sampling and testing quality control procedure of
pre- and post-processed flours was designed by the re-
search staff. Upon receipt, all groundnuts are sorted to
reduce AF. Prior to processing, multiple samples will be
drawn from maize and groundnut lots and tested for
moisture content and AF. The final products will be ac-
cepted if AF is ≤5 ppb and FUM is ≤2 ppm [38]. All
processed flours will be packaged for monthly consump-
tion to ensure no risk of spoilage or rancidity.
Adherence to the intervention
Accurately measuring adherence of a complementary
and supplementary food distribution program is difficult
[39–41]. Self-report, including calculation of a dis-
appearance rate tends to overestimate adherence, but
does not demand high resources [39]. Direct observation
and analysis of a biomarker, if available, can be more re-
liable but also time consuming and expensive. In the ab-
sence of a “perfect” method of assessing adherence, this
trial will use multiple methods: analysis of the urinary
biomarker AFM1, calculation of a disappearance rate
based on maternal report and maternal interviews about
infant feeding practices.
Urinary AFM1, a metabolite of aflatoxin, is a validated
biomarker that represents recent exposure in the past
2–3 days [42]. AFM1 will be used to measure short-term
adherence in a selected cohort of infants (described in
“Study timeline” below) at 9, 12, 15 and 18 months. Ad-
herence to the recommended frequency of cooking and
amount of pre-blended porridge flour and groundnut
flours cooked will be measured by calculating the daily
disappearance rate (# of kilograms provided - # kg
remaining/number of days since previous distribution)
of the provided foods in the cohort at 12 months. Fur-
ther probing to assess feeding practices will include re-
ported consumption by the index child in the previous
24 h and previous week, acceptance of the products by
the child, sharing by other family members and neigh-
bors, how leftovers are handled, the time it takes to
complete a package of foods and maternal acceptance of
cooking and the flavor of the foods. In both groups at all
time points, mothers will be asked about porridge feed-
ing practices (not exclusive to the provided porridge
flour), including the ingredients used in the porridge,
consistency of cooked porridge and frequency of
feeding.
Implementation Fidelity
Implementation fidelity is “the degree to which pro-
grams are implemented as intended” [43]. Monitoring
the fidelity of a trial intervention provides contextual in-
terpretation of the trial results and is useful for both in-
ternal and external validity [44]. For example, if the trial
finds no evidence of effect, was the biological hypothesis
flawed, the intervention poorly targeted to the biological
pathway (theory failure) or was this due to a poorly im-
plemented intervention (program failure)? Alternatively,
if the trial finds evidence of an effect on child growth
can it be demonstrated that the intervention was imple-
mented as designed and is likely to be successful in an
alternate setting? A Program Impact Pathway (PIP) ap-
proach will be used to monitor the intervention delivery
and maternal uptake [45, 46].
Prior to the start of the trial, we reviewed IYCF best-
practices and IYCF theory-based program evaluations to
design a schematic PIP highlighting critical actions and
behaviors that could drive or moderate intervention suc-
cess [45, 47, 48]. We then used this PIP to identify key
indicators to be tracked throughout the trail. These in-
clude: 1) timely delivery, quantity and quality of the pro-
ject foods, skin lotion, thermos flask and scoops, 2)
Table 1 Intervention activities











Behavior change communication on use on use of porridge flours:
Timing of introduction, frequency of feeding, density and composition
Promotion of 4:1 ratio of maize meal to groundnut powder
Promotion of use of groundnut flour in infant foods
Behavior change communication on use of porridge flours:
Timing of introduction, frequency of feeding, density and composition
Promotion of 4:1 ratio of maize meal to groundnut powder
Promotion of use of groundnut flour in infant foods
Provision of pre-blended porridge flours and groundnut flour monthly
Provision of thermos flask and scoop at 6 month visit
Provision of skin lotion monthly
Provision of thermos flask and scoop at 6 month visit
Phillips et al. BMC Public Health          (2020) 20:598 Page 5 of 11
timely delivery of and maternal attendance of CHW-led
education sessions, and 3) maternal uptake of promoted
IYCF behaviors.
There are three to four full time staff, including “Im-
plementation Officers” and a logistician, who are respon-
sible for delivery of the trial products. Receipt of trial
products will be recorded electronically. CHWs keep
paper records of IYCF sessions held and attendance at
these sessions, which will be reviewed and submitted to
the Implementation Officers on a monthly basis. Uptake
of behaviors is from self-report by the mother at all sur-
vey time points.
Study timeline
Mothers will meet with data collectors four times
throughout the study (Table 2). The first survey will be
conducted at recruitment, when the index infant is be-
tween 1.5–3 months of age. The second survey will take
place when the infant is 6 months of age, the third at 12
months and the fourth and final survey at 18 months of
age. We will also include a cohort of 600 infants (300
per group) who will be visited at 9 and 15 months, in
addition to the standard visits.
The surveys will assess demographic and economics of
the household, infant feeding practices, access to health-
care, household food security, maternal dietary diversity,
community health worker contact, and water, sanitation
and hygiene of the household. At the 6, 12, and 18-
month survey points anthropometric assessment of
weight, height, MUAC and head circumference will be
conducted in all infants. Blood collection will occur at
three time points (6, 12 and 18months) in all infants,
and urine collection only from the cohort of 600 infants
at five time points (6, 9, 12, 15 and 18 months). In a sub-
set of 250 household in the cohort, maize and groundnut
samples will be collected, as well as an assessment of ad-
herence to the intervention and 24-h recalls.
Data collection and management
Twenty-four data collectors will be hired at the peak of
the trial. All data collectors will be trained in research
ethics and Good Clinical Practices (GCP). Anthropome-
trists will be trained to measure recumbent length,
weight, MUAC and head circumference. Length will be
measured with a ShorrBoard© and weight using an ADE
M321600 Electronic Floor Scale with mother/baby tare
feature, recorded to the tenth decimal.
Survey data will be collected electronically, using
hand-held devices (Samsung Galaxy 7, KoBoToolbox
Platform), with paper copies provided as back up in case
of electronic failure. Data quality checks are built into
the electronic version of the survey, for example limiting
Table 2 Summary of data collection – location, method, timing and topic
Research Visit Recruitment 6month 9 montha 12month 12monthb 15montha 18month











WASH practices I/O I/O I/O
Exposure to CHW education;
infant morbidity
I I I I I I
Access to health care HC HC HC HC HC HC HC




Porridge- specific feeding practice
I I I I I
Adherence to intervention
(intervention group only)
I I I/O I I





Blood T T T
Urine T T T T T
HC Health Card, I Interview, M Measurement, O Observation, T Test, aCohort only, bCohort sub-set
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ranges of responses/measurements to those that are
within a credible range and consistency checks between
questions. The Data Quality Supervisor will check all
surveys and uploads encrypted data on a daily basis to
KoboToolbox. The Research Coordinator in Arusha will
monitor enrollment numbers, rejection/non-qualifier
numbers, drop-out rates, completed visit rates, anthro-
pometry and biological sample collection success rates
each week. The full data set will be encrypted, password-
protected and stored on Cornell IRB-approved locations.
Collection and Management of Biological Samples
Collection of blood and urine will be performed by certi-
fied Tanzanian nurses in health facilities following the
Standard Operating Procedures. These nurses will be
identified and hired in collaboration with the Kongwa
District Medical Officer.
Urine samples will be collected with a urine bag, trans-
ferred to a sterile container for transport and placed into
a cooler box with ice packs. Blood samples will be col-
lected using a vacutainer system with EDTA tubes,
placed in a Styrofoam rack then put into a cooler box
with ice packs. All samples will contain a barcode for
tracking. Samples will be transported to the research lab
at the Kongwa District Hospital within 4 hours of collec-
tion. The laboratory scientist in Kongwa will record and
catalog samples using a hand-held device (Samsung Gal-
axy 7, KoBoToolbox Platform), then process blood and
urine samples upon arrival from the field. Plasma will be
isolated and both plasma and urine aliquots will be
stored at -40F. Biohazard material and sharps will be dis-
carded through partnership with the Kongwa District
Hospital.
Randomization procedure
To capture the potential range of exposure across the
district, all facilities were included in the sampling
frame, and their unique catchment area is considered a
cluster. The randomization procedure was developed to
ensure close balance between the two groups on altitude
and number of EPI visits.
Altitude is associated with mycotoxin risk, with 1000–
1200 m considered the threshold for drier and colder
conditions in which toxin-producing fungi are less likely
to thrive. Number of EPI visits was used as a proxy for
health facility size, population density and access to re-
sources such as roads and markets.
The following steps were taken to randomized health
facilities:
1. Sort the health facilities by low versus high altitude
using the median of the district, 1200 m, as the cut-
off.
2. Sort the health facilities by size within each altitude
category, using 42 day immunization visit
attendance data from the most recent year of data
(August 2017–July 2018).
3. Group health facilities into successive pairs from
the top to the bottom of each altitude category.
Half of the pairs within a list were randomly
chosen. For the chosen pairs, the first health facility
in each pair was assigned to the experimental group
and the other health facility assigned to the control
group. For the pairs not chosen, the assignments
were reversed: the first health facility in each pair
was assigned to the control group and the other
health facility assigned to the experimental group.
Sample size calculation
The sample size calculation was estimated to detect a
difference of 0.2 LAZ score between the intervention
and control groups using the STATA (version 15.1)
command for two independent sample means in a CRT.
This difference in LAZ is believed to be clinically signifi-
cant and would therefore motivate public health
decision-making.
Using a one-sided test of independent sample means,
with a standard deviation of 1.2 Z, type I error of 0.05,
and power of 0.90, design effect of 2.0 (justified below)
and randomizing all 52 health facilities (26 per group),
the total sample size was calculated to be 2322 (1161 in-
fants per cluster). This also assumes a coefficient of vari-
ation of .14 for varying cluster size, based on previous
year’s data for EPI attendance at 42 days. A conservative
estimate of 20% loss to follow-up and infant mortality
indicates a total of 2787 infants, or 54 infants recruited
per health cluster annually or 4.5 infants per cluster per
month is needed. Therefore, if five infants per cluster
per month are recruited, that will results in a total of
3120 infants in the study, recognizing that in approxi-
mately six of the health facilities, it may be difficult to
recruit sufficient numbers based on the size of the popu-
lation served by the facility.
To estimate the design effect, we identified other
cluster-randomized trials with educational and/or food
provision interventions delivered through CHWs with
LAZ as an outcome [49–51]. Based on these studies, we
used an intraclass correlation coefficient of 0.02 to reach
our design effect of 2.0. This is in line with the estimated
design effects for stunting using population-based sur-
veys in three African countries calculated by Katz [52].
Cohort selection
Twenty-four health facilities (12 heath facility pairs)
were purposively selected to be the cohort sampling
frame, based on geographic accessibility of the facilities
themselves and their catchment households. At the 6
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month visit, when the randomized intervention begins,
2–3 mothers at these facilities are randomly selected
into the cohort on a monthly basis by pulling different
colored marbles from a bag. If a mother accepts partici-
pation in the cohort, there is an additional informed
consent procedure.
Statistical analysis and data analysis plan
All outcomes will be presented using descriptive statis-
tics; normally distributed data by the mean and standard
deviation (SD) and skewed distributions by the median
and interquartile range (IQR). AF biomarkers and food
contamination, usually skewed, will additionally be pre-
sented as geometric means and 95% CIs, medians and
IQRs. Binary and categorical variables will be presented
using counts and percentages. These outcomes will add-
itionally be presented by study group and season.
The primary analysis will compare LAZ at 18 months
between the control and intervention groups and will be
analyzed using a mixed-model, such as Stata GEE re-
gression procedure, to account for with-in cluster vari-
ance. The primary analyses will be intention-to-treat.
Secondary analyses will include:
 Intention-to-treat analyses of human mycotoxin
biomarker outcomes
 Analyses of mediation of mycotoxin biomarkers on
the primary outcomes, using path analysis and/or
regression approaches
 Adjusted estimates of the randomized treatment
effects on primary and secondary outcomes, using
multiple regression equations to adjust for
imbalances between randomized groups, and
potentially increase precision of the effect estimate.
For this analysis we will include covariates that differ
substantially between randomized groups and/or
that modify the intervention effect size by at least
10% when included in the model.
 Per-protocol analysis of those with the highest
contact with CHWs responsible for delivering the
intervention and those who report high adherence
to the intervention. In these analyses, we will
consider the CHW contact and adherence to the
intervention as ordinal variables defined by tertile or
quartile of the continuous variables.
 By sub-groups: socio-economic status, quartile, sex,
elevation of residence, quartiles of LAZ at 6 months
Trial results will be reported in accordance with the ex-
tended CONSORT guidance for cluster randomized trials.
Missing data
In the main analyses we will include all relevant continu-
ous covariates with less than 10% missing. For
categorical variables, we will create a dummy variable
for missing. For variables that have substantial missing
we will conduct sensitivity analyses with multiple imput-
ation to compare to the main analyses.
Ethics
This trial has been approved by the Cornell IRB
and the Tanzanian National Institute for Medical
Research (NIMR). Any protocol amendments have
been approved prior to implementation and updated
in ClinicalTrials.gov. Written informed consent is
asked and obtained by all participants in Kiswahili
prior to the start of data collection. Our informed
consent forms have been written for a population
with limited research experience and research
knowledge and contains multiple questions to check
for comprehension of the study and the partici-
pant’s rights. These forms are written specifically
for each group, since randomization is at the clus-
ter (health facility) level, prior to the start of re-
cruitment. Further consent is requested to store
biological samples for future use.
All staff, including community health workers who
have the most contact with mothers, were trained on the
trial’s Unexpected Events Reporting plan to ensure ap-
propriate and timely reporting to the Cornell IRB and
NIMR. Survey data will be reviewed for attrition, child
morbidity, any reports of protocol deviations on a
monthly basis. Participant complaints and expected or
unexpected events are received on a case-by-case basis
and are reported to the IRB according to our reporting
plan.
An independent Data Safety and Monitoring Board
(DSMB) was established, consisting of a biostatistician, a
pediatrician and a nutritionist. The DSMB will convene
three times – once around the time of the study’s launch
(completed August, 2019), near the end of recruitment
(completed February, 2020) and at the end of the trial.
The DSMB will monitor trial data at 6-monthly inter-
vals, beginning in August 2020. The following data are
included in the monitoring report, active complaints
from mothers about an index infant’s health, care-
seeking from clinic, doctor or hospital for baby illness,
stunting prevalence (LAZ < − 2), wasting prevalence
(WHZ < − 2) and possible severe acute malnutrition
(SAM). Infant deaths will also be reported to the DSMB
as soon as possible. The DSMB decided not set any stop-
ping rules.
Dissemination policy
The Bill and Melinda Gates Foundation, the funder of
this trial, requires an open access data policy. Therefore,
all manuscripts from this funded work will be open ac-
cess with the data underlying the published research
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results. More on this policy can be found: https://www.
gatesfoundation.org/how-we-work/general-information/
open-access-policy
Additionally, we will present our results with the
Kongwa District Council, as well as a final report to
NIMR and the Tanzanian Commission for Science and
Technology (COSTECH). We are not authorized to
share any results with the participants or communities
directly but can request the local government to share
only summary results (not results by health facility) to
assure confidentiality is upheld.
Discussion
Prior to initiation of field work, the researchers per-
formed a literature review about the ethics of conducting
a trial focused on mycotoxin exposure, studying general
bioethics and relevant randomized trials in environmen-
tal health and HIV treatment in low and middle income
countries (Phillips et al., manuscript in prep). The design
of this study attempts to balance risk and benefit to all
participants.
Alongside the trial, this project is also working towards
means to reduce AF and FUM in foods by innovating
various sorting technologies appropriate for low-input
food chains. We are performing extensive size and visual
sorting experiments of maize and groundnuts to reduce
of contamination and lead to improved grain sorting
techniques to reduce AF and FUM contamination.
The results of this trial will strengthen the understand-
ing the effect of AF exposure on growth in infants and
young child. This study has the potential to provide pol-
icy makers with valuable information about the potential
contribution of AF on growth retardation and to ultim-
ately benefit the most vulnerable populations where
growth deficiencies persist.
Appendix
Appendix 1: List of all secondary outcomes
1. To determine the effect of an intervention to
reduce AF on LAZ scores at 12 months and
stunting at 12 and 18 months
2. To determine the effect of an intervention to
reduce AF on weight for age Z scores (WAZ) at 12
months and 18 months and underweight at 12 and
18months
3. To examine the effect of an intervention to reduce
AF on mid-upper arm circumference and head
circumference at 12 and 18 months
4. To assess the effect of an intervention to reduce AF
on the blood biomarker AF-alb at 12 and 18
months
5. To assess the effect of an intervention to reduce AF
on the urinary biomarker AFM1 in a cohort of 600
infants at 9, 12, 15 and 18 months
6. To assess the effect of an intervention to reduce AF
on the urinary biomarker FUM in a cohort of 600
infants at 9, 12, 15 and 18 months
7. To describe the relationship between recent
consumption AF in food and AFM1 in urine in a
cohort of infants at 12 months
8. To determine the relationship between FUM in
food and urinary FUM biomarkers in a cohort of
infants at 12 months
9. To determine how demographics, geography and
climate modify spatial measures of food
consumption and food contamination with AF and
FUM
10. To determine how pre- and post-harvest practices
influence contamination of food with AF and FUM
11. To use blood and urinary biomarkers to
hypothesize mechanisms of AF-induced stunting at
12 and 18months, including a threshold of
exposure
12. To identify early life food and cultural behaviors
that may influence food choices and AF exposure
13. To investigate role AF and FUM co-exposure on
stunting, LAZ, underweight and WAZ at 12 and 18
months
14. To determine the effect of an intervention to
reduce AF on inflammatory markers (CRP and
TNFa) at 18 months of age
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